Massachusetts General Hospital | Heart Center

BiographyDr. Januzzi has been a member of the Massachusetts General Hospital Cardiology Division since 2000 where he is now the Director of the Cardiac Intensive Care Unit and an Associate Professor of Medicine at Harvard Medical School. 

Dr. Januzzi graduated first in his class from New York Medical College in 1994, and subsequently did a residency in Internal Medicine at the Brigham and Women's Hospital, followed by a cardiology and echocardiography fellowship at Massachusetts General Hospital.  Since joining the staff at MGH, Dr. Januzzi is an active clinician, with a focus on acute myocardial infarction, chronic coronary artery disease, acute heart failure, chronic heart failure, and aortic disease.  He is an active teacher, and has a busy research program, with a specific focus on cardiac biomarker testing.  He has published more than 150 manuscripts, and has edited 2 textbooks, and speaks widely on the topic.  He is the Director of the Cardiac Intensive Care Unit at the Massachusetts General Hospital, and is the Cardiologist to the Boston Red Sox.

Research

Dr. Januzzi has an active, world-recognized program in cardiac biomarker testing.  His main area of interest focuses on the natriuretic peptides are markers of heart failure diagnosis, prognosis, and management.

PublicationsDr. Januzzi has published more than 150 peer reviewed publications and has edited two text books.

Scholar program established

At age 81, Roman W. DeSanctis, MD, is one of the hospital’s most veteran and most beloved physicians. To honor the legendary MGH cardiologist, the Roman W. DeSanctis, MD, Endowed Distinguished Scholar in Medicine has been established through the generosity of donor Joan Fu and several others.

Cardiac biomarker levels strongly predict outcome of bypass surgery

Levels of a biomarker used in the diagnosis of heart attacks are almost universally elevated in patients who have undergone coronary-artery bypass grafting (CABG) and, when markedly elevated, powerfully predict the risk of complications.

Biomarker-guided heart failure treatment significantly reduces complications

Adding regular testing for blood levels of a biomarker of cardiac distress to standard care for the most common form of heart failure may significantly reduce the incidence of cardiovascular complications, a new MGH study finds.